2026-04-14T07:22:33Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4741632025-08-31T17:00:27Zcom_2072_98col_2072_378192

urn:hdl:2072/474163 Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C Notario Rincón, Lucía Cucurull, Marc Cerdà, Gabriela Sanz, Carolina Carcereny, Enric Muñoz-Mármol, Ana Hernández, Ainhoa Domènech, Marta Morán, Teresa Sanchez-Cespedes, Montse Costa, Marta Mate, Jose Luis Esteve, Anna Saigí, Maria Non-small cell lung cancer Lung adenocarcinoma KRAS PD-L1 Immunotherapy Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. Among all patients included, 47% carried KRAS G12C mutation whereas 53% harbored KRAS non-G12C mutations. PD-L1 status was available for 77% of cases, with higher expression among KRAS G12C tumors (p = 0.01). Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies. 2023 Article Instituto de Salud Carlos III CM19/0068 Instituto de Salud Carlos III JR20/00015 Frontiers in Oncology ; Vol. 13 (october 2023) open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/